Compare Main Street Capital Corporation (MAIN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Pfizer Inc — how do they compare? Main Street Capital Corporation trades at $54.03 (market cap $5.09B), while Pfizer Inc trades at $28.06 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 31.2× Main Street Capital Corporation's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and Pfizer Inc for 158 Days on average.
| MAIN | PFE | |
|---|---|---|
Market Cap | $5.09B | $158.56B |
Volume | 524,060 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $64.60 | $29.02 |
52-Week Low | $49.63 | $23.67 |
Typical Hold Time | 88 Days | 158 Days |
Enterprise Value | $7.54B | $210.06B |
Dividend Yield | 5.84% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.305, up 0.23% on the day, with a bearish technical outlook as moving averages and oscillators signal selling pressure. Fundamentally, the company maintains strong profitability with an 80.77% net income margin and a P/E of 10.94, though revenue declined to $592 million in 2025 from $601 million in 2024. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026. The stock pays consistent monthly dividends, with the latest being $0.27 per share.
The investment outlook is cautious; analyst consensus is a 'Hold' with a $58.33 price target, indicating modest upside. Risks include softening earnings, a premium valuation at 1.62x NAV, and sensitivity to interest rates. The bearish technicals and high hold ratings suggest limited near-term catalysts, but the dividend yield near 8% and robust ROE of 14.92% provide income support.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
